Zealand Pharma's Petrelintide Shows Double-Digit Weight Loss with Favorable GI Tolerability in Phase 2 Trial

Results from the Phase 2 ZUPREME-1 trial for Zealand Pharma's investigational amylin-based obesity drug, petrelintide, have been published in The Lancet Diabetes & Endocrinology and presented at the EASD 2026 annual meeting. The trial demonstrated mean reductions in body weight of up to 10.7% over 42 weeks. Notably, gastrointestinal adverse events were generally mild and occurred at rates similar to placebo, suggesting a potentially improved tolerability profile compared to existing incretin-based therapies.